Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Cancer prevalence in primary mitochondrial disease patients and their families. Ther Adv Rare Dis 2026;7:26330040261471914

Date

08/02/2026

Pubmed ID

42539989

Pubmed Central ID

PMC13424766

DOI

10.1177/26330040261471914

Scopus ID

2-s2.0-105046521244 (requires institutional sign-in at Scopus site)

Abstract

BACKGROUND: While somatic mitochondrial dysfunction occurs in diverse cancers, the association between oncogenesis and germline mitochondrial gene pathogenic variants remains unclear. Further, few clinical observations have been reported of cancer occurring in primary mitochondrial disease (PMD) patients.

OBJECTIVES: To improve understanding of the potential modulating role for PMD gene disorders in cancer prevalence.

DESIGN: 727 individuals, including 100 with PMD, from 97 unrelated families were retrospectively surveyed to assess their history of individual cancer occurrence.

METHODS: We evaluated survey responses by characterizing the cancer prevalence among the study cohort and comparing to the general U.S. population via the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database. Odds ratio calculation was performed to determine the association of survey responses and cancer prevalence.

RESULTS: Although overall cancer prevalence in PMD probands and their families was elevated compared to the NCI SEER rate (8800 vs 5600 cases per 100,000), odds ratio calculation determined that PMD did not significantly increase the likelihood of developing cancer, with a non-significant trend observed toward less cancer occuring in PMD that needs to be explored in further studies. Cancer prevalence was significantly correlated with advanced age. Significantly reduced prevalence of prostate cancer was seen across the entire cohort. Surprisingly, while low absolute prevalence (n = 3), a 9-fold increased odds ratio of cancer was seen in POLG patients relative to those with other causes of PMD.

CONCLUSION: No evidence of increased cancer odds was identified in a cohort of PMD patients and their close relatives. Interestingly, a possible inverse association, which did not reach statistical significance, was suggested between mitochondrial disease status and cancer odds. Future prospective investigations in larger PMD kindreds are warranted to validate and evaluate potential mechanistic relations between cancer prevalence and PMD.

Author List

Dalwadi S, Engelhardt NM, Muraresku CC, Keith K, Valverde KD, Nathanson KL, Falk MJ

Author

Marni Falk MD Executive Director, Professor in the Mellowes Center for Genomic Sciences and Precision Medicine department at Medical College of Wisconsin